Hilary Bergman

There is a positive bias in early trading after sharp declines in recent sessions. Pre-open gains in semiconductor names and mega cap stocks have supported the upside moves. Read more in the Morning Brew.

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

New Post: Navellier Top 5 Stocks for July - https://lnkd.in/g_unpB5k Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to prosper from the booming business in weight-loss drugs. As you may know, the company is known for its type 2 diabetes treatment, Mounjaro, and its weight-loss drug, Zepbound, as both have now received FDA approval. But Eli Lilly is far from a one-trick pony. Just this week, Eli Lilly announced that it was partnering with OpenAI in order to utilize its generative AI to develop antimicrobials for the treatment of drug-resistant pathogens. Company management noted antimicrobial resistance is an “overlooked threat,” and its partnership with OpenAI illustrates Eli Lilly’s “commitment to addressing significant health challenges experienced by people around the world.” Eli Lilly will release second-quarter results on August 8. The consensus estimate calls for earnings of $2.75 per share on $9.97 billion in revenue, which translates to 30.3% year-over-year earnings growth and 19.9% year-over-year revenue growth. The company also announced that it will pay a third-quarter dividend of $1.30 per share on September 10. All shareholders of record on August 15 will receive the dividend. The stock has a 0.6% dividend yield. LLY is a Conservative buy below $979. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Tra

New Post: Navallier Top 5 Stocks for May - https://lnkd.in/gmqzvKEe Investments Eli Lilly & Company Eli Lilly & Company (LLY) continues to experience unrelenting demand for its diabetes and weight-loss treatments. In fact, demand is so high that the FDA recently revealed that most doses of Mounjaro and Zepbound could be in limited supply through the end of the current quarter. In order to keep up with continuing demand, Eli Lilly plans to invest heavily in manufacturing and supply capacity for its injectable medicines like Mounjaro and Zepbound. Just this week, the pharmaceutical company announced plans to purchase a manufacturing facility from Nexus Pharmaceuticals. In the meantime, we’ll see exactly how robust demand has been for the company’s treatments next week. Eli Lilly is scheduled to release results for its first quarter in fiscal year 2024 before the stock market opens on Tuesday, April 30. First-quarter earnings are forecast to increase 52.5% year-over-year to $2.47 per share, up from $1.62 per share in the same quarter a year ago. Analysts have increased earnings estimates by nearly 8% in the past month, so a fourth-straight quarterly earnings surprise is likely. First-quarter sales are expected to rise 28.2% year-over-year to $8.92 billion. LLY is a Conservative buy below $801. SOM Technicals: 10-07-23: Closed at 567.87. Trade pressures are up. Volumes are now bullish. The next target up is 575.41. 10-14-23: closed at 609.20. Trade pressures are up and trending. Volumes are now bearish. The next target up is 636.00. There is the large gap near 460 to fill. 10-27-23: Closed at 560.23. Trade pressures are down. Volumes are bearish. The next target down is 559.00. 11-3-23: Closed at 567.81. Trade pressures are up but turning down. Volumes are neutral. The next target down is 535.00. 11-10-23: Closed at 597.50. Trade pressures are down. Volumes are neutral. Rolling over after the rally, the next target down is 544.70. 11-17-23: Closed at 591.74. Trade pressures are down but rising. Volumes are neutral. The next target up is 629.97. 11-26-23: Closed at 601.10. Trade pressures are up Volumes are neutral. In consolidation. The next target up is 619.40. 12-1-23: Closed at 584.04. Trade pressures are down. Volumes are bearish. The next target down is 573.69. 12-9-23: Closed at 598.05. Trade pressures are up. Volumes are bullish. The next target up is 611.72. 12-15-23: Closed at 571.22. Trade pressures are down. Volumes are down. The next target down is 55.74 then 529.00. 12-30-23: Closed at 581.60. Trade pressures are up. Volumes are bullish. The next target down is 560.26. 1-6-24: Closed at 618.55.  Trade pressures are up. Volumes are neutral. The next target up is a retest of the 636.15 target. 1-12-24: Closed at 642.92. Trade pressures are up. Volumes are bullish. The next target up is 664.52. 1-20-24: Closed at 628.58. Trade p

Our Midyear Outlook ‘24 webinar will be held on July 18! Register now to hear Carson Group’s Ryan Detrick, Chief Market Strategist, and Sonu Varghese, VP, Global Macro Strategist dive into what the rest of 2024 might bring. Detrick and Varghese will provide valuable insights in this webinar, including:    ·       What to keep an eye on in the markets  ·       What moves to expect from the Fed  ·       What to expect from Washington Get a better understanding of what the rest of the year might bring from two leading voices within the financial services industry. [Register to attend the webinar.] https://lnkd.in/gJ_e28UY